173 related articles for article (PubMed ID: 21931991)
1. Ammonium pyrrolidine dithiocarbamate and RS 102895 attenuate opioid withdrawal in vivo and in vitro.
Rehni AK; Singh N
Psychopharmacology (Berl); 2012 Mar; 220(2):427-38. PubMed ID: 21931991
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological modulation of geranylgeranyltransferase and farnesyltransferase attenuates opioid withdrawal in vivo and in vitro.
Rehni AK; Singh TG
Neuropharmacology; 2013 Aug; 71():19-26. PubMed ID: 23415632
[TBL] [Abstract][Full Text] [Related]
3. Modulation of histone deacetylase attenuates naloxone-precipitated opioid withdrawal syndrome.
Rehni AK; Singh N; Rachamalla M; Tikoo K
Naunyn Schmiedebergs Arch Pharmacol; 2012 Jun; 385(6):605-19. PubMed ID: 22362134
[TBL] [Abstract][Full Text] [Related]
4. In vivo and in vitro attenuation of naloxone-precipitated experimental opioid withdrawal syndrome by insulin and selective KATP channel modulator.
Singh P; Sharma B; Gupta S; Sharma BM
Psychopharmacology (Berl); 2015 Jan; 232(2):465-75. PubMed ID: 25059539
[TBL] [Abstract][Full Text] [Related]
5. Nuclear factor-kappa-B inhibitor modulates the development of opioid dependence in a mouse model of naloxone-induced opioid withdrawal syndrome.
Rehni AK; Bhateja P; Singh TG; Singh N
Behav Pharmacol; 2008 May; 19(3):265-9. PubMed ID: 18469544
[TBL] [Abstract][Full Text] [Related]
6. Blockade of endocannabinoid hydrolytic enzymes attenuates precipitated opioid withdrawal symptoms in mice.
Ramesh D; Ross GR; Schlosburg JE; Owens RA; Abdullah RA; Kinsey SG; Long JZ; Nomura DK; Sim-Selley LJ; Cravatt BF; Akbarali HI; Lichtman AH
J Pharmacol Exp Ther; 2011 Oct; 339(1):173-85. PubMed ID: 21719468
[TBL] [Abstract][Full Text] [Related]
7. Involvement of nuclear factor-kB in the expression of opiate withdrawal.
Capasso A
Prog Neuropsychopharmacol Biol Psychiatry; 2001 Aug; 25(6):1259-68. PubMed ID: 11474844
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological modulation of leukotriene D(4) attenuates the development of opioid dependence in a mouse model of naloxone-induced opioid withdrawal syndrome.
Rehni AK; Singh I; Singh N; Bansal N; Bansal S; Kumar M
Eur J Pharmacol; 2008 Nov; 598(1-3):51-6. PubMed ID: 18840427
[TBL] [Abstract][Full Text] [Related]
9. Yiguanjian cataplasm attenuates opioid dependence in a mouse model of naloxone-induced opioid withdrawal syndrome.
Gao S; Gao H; Fan Y; Zhang G; Sun F; Zhao J; Li F; Yang Y; Wang K
J Tradit Chin Med; 2016 Aug; 36(4):464-70. PubMed ID: 28459510
[TBL] [Abstract][Full Text] [Related]
10. Suppression of naloxone-precipitated withdrawal jumps in morphine-dependent mice by stimulation of prostaglandin EP3 receptor.
Nakagawa T; Minami M; Katsumata S; Ienaga Y; Satoh M
Br J Pharmacol; 1995 Nov; 116(6):2661-6. PubMed ID: 8590986
[TBL] [Abstract][Full Text] [Related]
11. The role of nitric oxide in the development of opioid withdrawal induced by naloxone after acute treatment with mu- and kappa-opioid receptor agonists.
Capasso A; Sorrentino L; Pinto A
Eur J Pharmacol; 1998 Oct; 359(2-3):127-31. PubMed ID: 9832382
[TBL] [Abstract][Full Text] [Related]
12. Differential influence of D1 and D2 dopamine receptors on acute opiate withdrawal in guinea-pig isolated ileum.
Capasso A; Sorrentino L
Br J Pharmacol; 1997 Mar; 120(6):1001-6. PubMed ID: 9134209
[TBL] [Abstract][Full Text] [Related]
13. Opioid and cannabinoid modulation of precipitated withdrawal in delta(9)-tetrahydrocannabinol and morphine-dependent mice.
Lichtman AH; Sheikh SM; Loh HH; Martin BR
J Pharmacol Exp Ther; 2001 Sep; 298(3):1007-14. PubMed ID: 11504797
[TBL] [Abstract][Full Text] [Related]
14. Modulation of src-kinase attenuates naloxone-precipitated opioid withdrawal syndrome in mice.
Rehni AK; Singh N
Behav Pharmacol; 2011 Apr; 22(2):182-90. PubMed ID: 21285874
[TBL] [Abstract][Full Text] [Related]
15. Potential involvement of tyrosine phosphatase and calpain-related pathways in opioid withdrawal syndrome in mice.
Rehni AK; Singh N
Behav Pharmacol; 2012 Jun; 23(3):302-9. PubMed ID: 22495184
[TBL] [Abstract][Full Text] [Related]
16. Quantitative evaluation of opioid withdrawal signs in rats repeatedly treated with morphine and injected with naloxone, in the absence or presence of the antiabstinence agent clonidine.
Pinelli A; Trivulzio S
J Pharmacol Toxicol Methods; 1997 Nov; 38(3):117-31. PubMed ID: 9523765
[TBL] [Abstract][Full Text] [Related]
17. Effects of the NF-kappaB inhibitor pyrrolidine dithiocarbamate on experimentally induced autoimmune anterior uveitis.
Yang CH; Fang IM; Lin CP; Yang CM; Chen MS
Invest Ophthalmol Vis Sci; 2005 Apr; 46(4):1339-47. PubMed ID: 15790900
[TBL] [Abstract][Full Text] [Related]
18. Effect of salmon-calcitonin on in vitro opioid withdrawal.
Alfaro MJ; Fernández B; Goicoechea C; Martín MI
Jpn J Pharmacol; 1997 Sep; 75(1):101-4. PubMed ID: 9334892
[TBL] [Abstract][Full Text] [Related]
19. Nitric oxide synthase inhibitors attenuate acute and chronic morphine withdrawal response in the rat locus coeruleus: an in vivo voltammetric study.
Hall S; Milne B; Jhamandas K
Brain Res; 1996 Nov; 739(1-2):182-91. PubMed ID: 8955938
[TBL] [Abstract][Full Text] [Related]
20. Withdrawal contractures of guinea-pig isolated ileum after acute activation of kappa-opioid receptors.
Morrone LA; Romanelli L; Amico MC; Valeri P
Br J Pharmacol; 1993 May; 109(1):48-52. PubMed ID: 8388301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
